Within the last few hours CNBC's Pharmaceuticals Reporter Mike Huckman broke the news that Boston Scientific has locked up a huge account, but at what price?
Because drug-coated stents are high profit margin devices every little shift in market share between Boston Scientific and Johnson and Johnson can have an impact on their bottom lines...even if they're apparently doing more aggressive bulk-buy discounting.
A source close to the negotiations says that the Cleveland Clinic, with one of the nation's most prominent cardiology centers...has signed a two-year contract to buy only Boston Scientific stents. That's about $18 million worth of business each year.